Phathom Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference

FLORHAM PARK, N.J., April 03, 2025 (GLOBE NEWSWIRE) — Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today that members of the management team will participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Tuesday, April 8th, 2025, at 10:15 am ET.

Company management will also participate in one-on-one meetings during the conference, which will run from April 7-10, 2025.

To access the live webcast and archived recording of the event, visit the Events & Presentations section of the Phathom website at https://investors.phathompharma.com/news-events/events-and-presentations. The recording will be available for 90 days following the conclusion of the meeting.

About Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases. Phathom has in-licensed the exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB) that is currently marketed in the United States as VOQUEZNA® (vonoprazan) tablets for the relief of heartburn associated with Non-Erosive GERD in adults, the healing and maintenance of healing of Erosive GERD in adults and relief of associated heartburn, in addition to VOQUEZNA® TRIPLE PAK® (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) and VOQUEZNA® DUAL PAK® (vonoprazan tablets, amoxicillin capsules) for the treatment of H. pylori infection in adults. For more information about Phathom, visit the company’s website at www.phathompharma.com and follow on LinkedIn and X.

MEDIA CONTACT
Nick Benedetto
1-877-742-8466
media@phathompharma.com

INVESTOR CONTACT
Eric Sciorilli
1-877-742-8466
ir@phathompharma.com

© 2025 Phathom Pharmaceuticals. All rights reserved. VOQUEZNA, VOQUEZNA DUAL PAK, VOQUEZNA TRIPLE PAK, Phathom Pharmaceuticals, and their respective logos are registered trademarks of Phathom Pharmaceuticals, Inc.

Staff

Recent Posts

Streamline Healthcare Solutions Appoints Danny Gladden, MBA, MSW, LCSW, as Chief Clinical Officer

OAK BROOK, Ill.--(BUSINESS WIRE)--Streamline Healthcare Solutions announced the appointment of Danny Gladden, MBA, MSW, LCSW,…

3 hours ago

Lunai Bioworks, Inc. Issues Letter to Shareholders

SACRAMENTO, Calif. , Feb. 9, 2026 /PRNewswire/ -- Dear Shareholders,We have completed our AI platform in…

3 hours ago

Medical Simulation Market worth $7.23 billion by 2030 | MarketsandMarkets™

DELRAY BEACH, Fla., Feb. 9, 2026 /PRNewswire/ -- According to MarketsandMarkets™, the Medical Simulation Market is projected…

3 hours ago

Stryker introduces Mako Handheld Robotics with the limited market release of Mako RPS

PORTAGE, Mich., Feb. 9, 2026 /PRNewswire/ -- Stryker (NYSE: SYK), a global leader in medical technologies,…

3 hours ago

CiteAb Launches New Explore Platform for Streamlined Research Antibody & Reagent Selection

Leading life science database launches new scientific image search tool and improved reagent search engine…

3 hours ago

Tiger Group Offers New & Late-Model GMP Biopharma Manufacturing and QC Laboratory Equipment and Inventory in Online Auction

Facility-closure sale of equipment from SoCal-based GenVivo opens on Feb. 11.PASADENA, Calif., Feb. 9, 2026…

3 hours ago